Received Feb 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19-2 | COVID19 (COVID19 (PFIZER-BIONTECH BIVALENT)) | PFIZER\BIONTECH | 5 | GL0446 | IM / LA |
| FLUA4 | INFLUENZA (SEASONAL) (FLUAD QUADRIVALENT) | SEQIRUS, INC. | UNK | 346378 | IM / RA |
Reported Symptoms: 10054112:HOSPITALISATION; 10067923:VACCINE BREAKTHROUGH INFECTION; 10084401:COVID-19 RESPIRATORY INFECTION; Narrative: Patient is a 71 year old MALE with PMH of recent CAP PNA treated with inpatient stay and antibiotics presented to ED from assisted care facility for 4-5 days of increasing work of breathing, SOB, and wheezing. Patient found to be Covid positive and hypoxic to the mid 80s. H&P from 8/9/24 expressed concern for potential undiagnosed COPD based on extensive tobacco use history. Patient treated with remdesivir and dexamethasone and discharged back to assisted living facility. Other Relevant HX: PMH of recent CAP PNA treated with inpatient stay and antibiotics, persistent leukocytosis, mechanical aortic valve, mitral valve stenosis, HTN, HLD, renal cysts, BPH, GERD, CKDstage 3, Ulcerative colitis, and paroxysmal a-fib with extensive tobacco use history, concern for COPD. Other: Hospitalization for treatment of Covid infection s/p vaccination
Positive Covid-19 test CXR: no sign of acute cardiopulmonary disease CTA Chest: No PE